Skip to main content
main-content
Erschienen in: Die Anaesthesiologie 6/2022

25.05.2022 | Akutes Koronarsyndrom | CME

Das akute Koronarsyndrom in der prähospitalen Phase und in der Notaufnahme

verfasst von: René Brütsch, Ralf Zahn, Prof. Dr. Uwe Zeymer

Erschienen in: Die Anaesthesiologie | Ausgabe 6/2022

zum CME-Kurs Einloggen, um Zugang zu erhalten

Zusammenfassung

Das akute Koronarsyndrom ist der häufigste Grund für einen Rettungsdiensteinsatz in Deutschland. So resultieren in etwa 20–25 % aller Einsätze aus der Indikation Verdacht auf akutes Koronarsyndrom. Ein erheblicher Anteil der Gesamtsterblichkeit entfällt auf die präklinische Phase. Folglich sind in dieser frühen Phase eine zielgerichtete Diagnostik und Therapie von besonderer Bedeutung. Dieses Manuskript gibt Empfehlungen für das Vorgehen bei Patienten mit akuten Koronarsyndrom in der prähospitalen Phase und der Notaufnahme.
Literatur
1.
Zurück zum Zitat Roffi M, Patrono C, Collet JP et al (2016) 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 37(3):267–315 CrossRef Roffi M, Patrono C, Collet JP et al (2016) 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 37(3):267–315 CrossRef
2.
Zurück zum Zitat Ibanez B, James S, Agewall S et al (2017) 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European society of cardiology (ESC). Eur Heart J. https://​doi.​org/​10.​1093/​eurheartj/​ehx393 Ibanez B, James S, Agewall S et al (2017) 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European society of cardiology (ESC). Eur Heart J. https://​doi.​org/​10.​1093/​eurheartj/​ehx393
3.
Zurück zum Zitat Claeys MJ, Ahrens I, Sinnaeve P et al (2017) The organisation of chest pain units: position paper of the acute cardiovascular care association. Eur Heart J Acute Cardiovasc Care 6:203–211 CrossRef Claeys MJ, Ahrens I, Sinnaeve P et al (2017) The organisation of chest pain units: position paper of the acute cardiovascular care association. Eur Heart J Acute Cardiovasc Care 6:203–211 CrossRef
4.
Zurück zum Zitat DETO2X–SWEDEHEART Investigators, Hofmann R, James SK, Jernberg T et al (2017) Oxygen therapy in suspected acute myocardial infarction. N Engl J Med 377(13):1240–1249 CrossRef DETO2X–SWEDEHEART Investigators, Hofmann R, James SK, Jernberg T et al (2017) Oxygen therapy in suspected acute myocardial infarction. N Engl J Med 377(13):1240–1249 CrossRef
5.
Zurück zum Zitat ISIS‑2 Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected myocardial infarction. Lancet 2:349–360 ISIS‑2 Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected myocardial infarction. Lancet 2:349–360
6.
Zurück zum Zitat Zeymer U, Hohlfeld T, Vom Dahl J et al (2017) Prospective, randomised trial of the time dependent antiplatelet effects of 500 mg and 250 mg acetylsalicylic acid i.v. and 300 mg p.o. in ACS (ACUTE). Thromb Haemost 117(3):625–635 CrossRef Zeymer U, Hohlfeld T, Vom Dahl J et al (2017) Prospective, randomised trial of the time dependent antiplatelet effects of 500 mg and 250 mg acetylsalicylic acid i.v. and 300 mg p.o. in ACS (ACUTE). Thromb Haemost 117(3):625–635 CrossRef
7.
Zurück zum Zitat Yusuf S, Zhao F, Mehta SR et al (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494–502 CrossRef Yusuf S, Zhao F, Mehta SR et al (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494–502 CrossRef
8.
Zurück zum Zitat Montalescot G, Sideris G, Meulemann C, Bal-dit Sollier C (2006) A randomized comparison of high clopidogrel loading doses in patients with non-ST segment elevation acute coronary syndromes. The ALBION trial. J Am Coll Cardiol 48:931–938 CrossRef Montalescot G, Sideris G, Meulemann C, Bal-dit Sollier C (2006) A randomized comparison of high clopidogrel loading doses in patients with non-ST segment elevation acute coronary syndromes. The ALBION trial. J Am Coll Cardiol 48:931–938 CrossRef
9.
Zurück zum Zitat Mehta S, Tanguay J, Eikelboom J et al (2010) Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (Current OASIS 7): a randomised factorial trial. Lancet 376:1233–1243 CrossRef Mehta S, Tanguay J, Eikelboom J et al (2010) Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (Current OASIS 7): a randomised factorial trial. Lancet 376:1233–1243 CrossRef
10.
Zurück zum Zitat Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel vs. clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001–2015 CrossRef Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel vs. clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001–2015 CrossRef
11.
Zurück zum Zitat Wallentin L, Becker R, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057 CrossRef Wallentin L, Becker R, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057 CrossRef
12.
Zurück zum Zitat Bagai A, Goodman SG, Cantor WJ et al (2018) Duration of ischemia and treatment effects of pre- versus in-hospital ticagrelor in patients with ST-segment elevation myocardial infarction: Insights from the ATLANTIC study. Am Heart J 196:56–64 CrossRef Bagai A, Goodman SG, Cantor WJ et al (2018) Duration of ischemia and treatment effects of pre- versus in-hospital ticagrelor in patients with ST-segment elevation myocardial infarction: Insights from the ATLANTIC study. Am Heart J 196:56–64 CrossRef
13.
Zurück zum Zitat Zeymer U, Mochmann HC, Mark B et al (2015) Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction). JACC Cardiovasc Interv 8:147–154 CrossRef Zeymer U, Mochmann HC, Mark B et al (2015) Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction). JACC Cardiovasc Interv 8:147–154 CrossRef
14.
Zurück zum Zitat ACCOAST Investigators, Montalescot G, Collet JP et al (2014) Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI study. J Am Coll Cardiol 64(24):2563–2571 CrossRef ACCOAST Investigators, Montalescot G, Collet JP et al (2014) Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI study. J Am Coll Cardiol 64(24):2563–2571 CrossRef
15.
Zurück zum Zitat Yusuf S, Mehta SR, Chrolavicius S et al (2006) Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354(14):1464–1476 CrossRef Yusuf S, Mehta SR, Chrolavicius S et al (2006) Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354(14):1464–1476 CrossRef
16.
Zurück zum Zitat Ponikowski P et al (2016) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37(27):2129–2200 CrossRef Ponikowski P et al (2016) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37(27):2129–2200 CrossRef
Metadaten
Titel
Das akute Koronarsyndrom in der prähospitalen Phase und in der Notaufnahme
verfasst von
René Brütsch
Ralf Zahn
Prof. Dr. Uwe Zeymer
Publikationsdatum
25.05.2022
Verlag
Springer Medizin
Erschienen in
Die Anaesthesiologie / Ausgabe 6/2022
Print ISSN: 2731-6858
Elektronische ISSN: 2731-6866
DOI
https://doi.org/10.1007/s00101-022-01129-4